Kadhim Doaa Jawad, Azari Hanieh, Sokhangouy Saeideh Khorshid, Hassanian Seyed Mahdi, Alshekarchi Hawraa Ibrahim, Goshayeshi Ladan, Goshayeshi Lena, Abbaszadegan Mohammad Reza, Khojasteh-Leylakoohi Fatemeh, Khazaei Majid, Gataa Ibrahim Saeed, Peters Godefridus J, A Ferns Gordon, Batra Jyotsna, Lam Alfred King-Yin, Giovannetti Elisa, Avan Amir
Metabolic Syndrome Research Center, Mashhad University of Medical Sciences, Mashhad 91779-48564, Iran.
Medical Genetics Research Center, Mashhad University of Medical Sciences, Mashhad 91886-17871, Iran.
Genes (Basel). 2024 Apr 9;15(4):474. doi: 10.3390/genes15040474.
Colorectal cancer (CRC) imposes a significant healthcare burden globally, prompting the quest for innovative biomarkers to enhance diagnostic and therapeutic strategies. This study investigates the GPSM) family across several cancers and presents a comprehensive pan-cancer analysis of the gene across several gastrointestinal (GI) cancers. Leveraging bioinformatics methodologies, we investigated expression patterns, protein interactions, functional enrichments, prognostic implications, genetic alterations, and immune infiltration associations. Furthermore, the expression of the gene was analyzed using real-time analysis. Our findings reveal a consistent upregulation of expression in all GI cancer datasets analyzed, suggesting its potential as a universal biomarker in GI cancers. Functional enrichment analysis underscores the involvement of in vital pathways, indicating its role in tumor progression. The prognostic assessment indicates that elevated expression correlates with adverse overall and disease-free survival outcomes across multiple GI cancer types. Genetic alteration analysis highlights the prevalence of mutations, particularly missense mutations, in . Furthermore, significant correlations between expression and immune cell infiltration are observed, suggesting its involvement in tumor immune evasion mechanisms. Collectively, our study underscores the multifaceted role of in GI cancers, particularly in CRC, emphasizing its potential as a promising biomarker for prognosis and therapeutic targeting. Further functional investigations are warranted to elucidate its clinical utility and therapeutic implications in CRC management.
结直肠癌（CRC）在全球范围内给医疗保健带来了沉重负担，这促使人们寻求创新的生物标志物以改进诊断和治疗策略。本研究调查了多种癌症中的GPSM家族，并对几种胃肠道（GI）癌症中的该基因进行了全面的泛癌分析。利用生物信息学方法，我们研究了其表达模式、蛋白质相互作用、功能富集、预后意义、基因改变以及免疫浸润关联。此外，使用实时分析对该基因的表达进行了分析。我们的研究结果显示，在所分析的所有GI癌症数据集中，其表达均一致上调，表明它在GI癌症中具有作为通用生物标志物的潜力。功能富集分析强调了其在重要通路中的参与，表明其在肿瘤进展中的作用。预后评估表明，在多种GI癌症类型中，其表达升高与不良的总生存和无病生存结果相关。基因改变分析突出了该基因中突变的普遍性，特别是错义突变。此外，观察到其表达与免疫细胞浸润之间存在显著相关性，表明它参与了肿瘤免疫逃逸机制。总体而言，我们的研究强调了其在GI癌症，特别是CRC中的多方面作用，突出了其作为预后和治疗靶点的有前景生物标志物的潜力。有必要进行进一步的功能研究，以阐明其在CRC管理中的临床效用和治疗意义。
